Lilly to Buy Centessa for OX2R Sleep Drugs Eli Lilly announced acquisition of Centessa on Mar 31, 2026 (Investing.com). Narcolepsy prevalence estimated at ~0.05%; deal terms pending disclosure.

Lilly to Buy Centessa for OX2R Sleep Drugs: Eli Lilly announced acquisition of Centessa on Mar 31, 2026 (Investing.com). Narcolepsy prevalence estimated at ~0.05%; deal terms pending disclosure. 👈 Read full analysis #EliLilly #Centessa #SleepDrugs #Narcolepsy #OX2R

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs - Replaye Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake.

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
replaye.com/lilly-to-spe...

#News #EliLilly #Centessa #Sleep #Drugs #Health

Lilly Acquires Centessa for Up to $7.8B Eli Lilly agreed to buy Centessa for up to $7.8bn (announced Mar 31, 2026), targeting experimental narcolepsy drugs for a condition affecting ~0.05% of the population.

Lilly Acquires Centessa for Up to $7.8B: Eli Lilly agreed to buy Centessa for up to $7.8bn (announced Mar 31, 2026), targeting experimental narcolepsy drugs for a condition affecting ~0.05% of the population. 👈 Read full analysis #EliLilly #Centessa #PharmaNews #Biotech #Narcolepsy

Eli Lilly Buys Centessa for $6.3B to Bolster Sleep Drugs Eli Lilly agreed to buy Centessa for $6.3bn on Mar 31, 2026, expanding its sleep-medicine pipeline and signaling continued program-focused M&A in pharma.

Eli Lilly Buys Centessa for $6.3B to Bolster Sleep Drugs: Eli Lilly agreed to buy Centessa for $6.3bn on Mar 31, 2026, expanding its sleep-medicine pipeline and signaling continued program-focused M&A in… 👈 Read full analysis #EliLilly #Centessa #PharmaMergers #SleepMedicine #HealthcareInnovation

Centessa Soars on $6.3bn Lilly Takeover Eli Lilly offered $6.3bn for Centessa on Mar 31, 2026, triggering a sharp re-rating; deal sets a new benchmark for mid-cap biotech exits.

Centessa Soars on $6.3bn Lilly Takeover: Eli Lilly offered $6.3bn for Centessa on Mar 31, 2026, triggering a sharp re-rating; deal sets a new benchmark for mid-cap biotech exits. 👈 Read full analysis #Centessa #EliLilly #Biotech #MergersAndAcquisitions #FinanceNews

ナルコレプシー治療薬開発の進展: ネクセラファーマが3.5百万米ドル受領 ネクセラファーマ株式会社は、Centessa 社が開発中のナルコレプシー治療薬ORX750の第Ⅱ相臨床試験開始に伴い、3.5百万米ドルを受け取ることを発表しました。この治療薬は、オレキシン2受容体に作用し、ナルコレプシー1型、2型、および特発性過眠症に効果が期待されています。

ナルコレプシー治療薬開発の進展: ネクセラファーマが3.5百万米ドル受領 #ネクセラファーマ #ORX750 #Centessa

ネクセラファーマ株式会社は、Centessa 社が開発中のナルコレプシー治療薬ORX750の第Ⅱ相臨床試験開始に伴い、3.5百万米ドルを受け取ることを発表しました。この治療薬は、オレキシン2受容体に作用し、ナルコレプシー1型、2型、および特発性過眠症に効果が期待されています。